

GenCore version 5.1.5
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model
Run on: June 1, 2003, 17:59:15 ; Search time 497 seconds
(without alignments)
10113.602 Million cell updates/sec

Title: US-09-625-573-1
Perfect score: 2232
Sequence: 1 GGATTGACCAAGGACGATT.....TATAACTATGTTGATAAAG 2232

Scoring table: OLIGO_NUC
Gapop 60.0, Gapext 60.0

Searched: 2185239 seqs, 112599159 residues

Word size : 0
Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 45 summaries

Database : N_Geneseq_101002:*

- 1: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1980.DAT:*
- 2: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1981.DAT:*
- 3: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1982.DAT:*
- 4: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1983.DAT:*
- 5: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1984.DAT:*
- 6: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1985.DAT:*
- 7: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1986.DAT:*
- 8: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1987.DAT:*
- 9: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1988.DAT:*
- 10: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1989.DAT:*
- 11: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1990.DAT:*
- 12: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1991.DAT:*
- 13: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1992.DAT:*
- 14: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1993.DAT:*
- 15: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1994.DAT:*
- 16: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1995.DAT:*
- 17: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1996.DAT:*
- 18: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1997.DAT:*
- 19: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1998.DAT:*
- 20: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA1999.DAT:*
- 21: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2000.DAT:*
- 22: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT:*
- 23: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT:*
- 24: /SIDS2/gcgdata/geneseq/geneseq-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2232	100.0	2232	16 AAO96297	Human monocyte che
2	1152	51.6	143068	21 AAF21105	Human low adenosin
3	1152	51.6	143068	21 AAF21272	Human low adenosin
4	1152	51.6	143068	21 AAA34983	Human adenosine re
5	1152	51.6	143068	21 AAA35150	Human adenosine re
6	1152	51.6	143068	21 ABL68124	Ovary cancer relat
7	1152	51.6	149412	21 ABL35151	Human adenosine re
8	1152	51.6	152740	21 AAF21273	Human low adenosin
9	980	43.9	1979	16 AAO96298	Human monocyte che

10	941	42.2	1083	22	AA512140	Human wild-type CC
11	890	39.9	1083	22	AA512139	Human CCR2-64I pol
12	839	37.6	1083	18	AA5196976	Human monocyte che
13	839	37.6	1083	23	AA5197976	Non-endogenous hum
14	65	2.9	461	20	AAV84136	HIV-1 co-receptor
15	65	2.9	792	18	AA5190116	cDNA for inactive
16	65	2.9	1056	22	AA513198	Human G-protein ch
17	65	2.9	1056	22	AA513299	Human G-protein ch
18	65	2.9	1056	24	ABK51870	DNA encoding human
19	65	2.9	1059	19	AAV23992	Human CC-CKR5 codi
20	65	2.9	1059	23	AA5197978	Non-endogenous hum
21	65	2.9	1059	24	AA5197319	Human chemokine (C
22	65	2.9	1071	20	AAV84125	HIV-1 co-receptor
23	65	2.9	1225	19	AA5176920	DNA encoding human
24	65	2.9	1225	24	AA5176920	Human CC chemokine
25	65	2.9	1225	24	AA5176920	Human CCR5 Gln 55
26	65	2.9	1255	19	AA5176919	DNA encoding human
27	65	2.9	1344	20	AAV84126	HIV-1 co-receptor
28	65	2.9	1376	22	AAH26903	Human HIV-1 co-rec
29	65	2.9	1414	18	AA514042	Human G-protein ch
30	65	2.9	1414	21	AA514042	Human G-protein ch
31	65	2.9	1414	22	AA514042	Human HDGFR10 cDNA
32	65	2.9	1414	22	AA514042	DNA encoding human
33	65	2.9	1414	22	AA514042	cDNA for inactive
34	65	2.9	1414	22	AA514042	cDNA for human CCR
35	65	2.9	1414	24	ABK51853	Human CCR5 cDNA se
36	65	2.9	1442	18	AA5190118	Human chemokine re
37	65	2.9	1477	18	AA5190117	Human chemokine re
38	65	2.9	1477	22	AA5190117	Human chemokine re
39	65	2.9	1557	18	AA519542	Human low adenosin
40	65	2.9	3383	18	AA519542	Human adenosine re
41	65	2.9	3383	21	AA519542	Human chemokine re
42	65	2.9	3383	21	AA519542	Human chemokine re
43	65	2.9	3383	22	AA519542	Human chemokine re
44	65	2.9	5674	20	AA519542	Human chemokine (C
45	65	2.9	9141	24	AA519542	Human chemokine (C

ALIGNMENTS

RESULT 1
AAO96297
ID AAO96297 standard; cDNA; 2232 BP.

XX AC AAO96297;

XX DT 29-DEC-1995 (first entry)

XX DE Human monocyte chemoattractant protein-1 receptor MCP-1RA.

XX DE Monocyte chemoattractant protein-1 receptor; MCR-1R; chemokine; ss.

XX KW Homo sapiens.

XX OS Location/Qualifiers

XX FT 40...1161

XX FT /*tag= a

XX PN WO9519436-A.

XX PD 20-JUL-1995.

XX PF 11-JAN-1995; 95WO-US00476.

XX PR 13-JAN-1994; 94US-0182962.

XX PA (REGC) UNIV CALIFORNIA.

XX PI Charo I, Coughlin S;

XX DR WPI; 1995-263866/34.

XX DR P-PSDB; AAR79165.

1681 CTTCTAGGCTTGTGCTCCAAAGACCTTTTCTGTTTCTTTTGTATCATTTATGATCATGC 1740
Db CTTCTAGGCTTGTGCTCCAAAGACCTTTTGTGTTTCTTTTGTATCATTTATGATCATGC 1740
1741 GTTTAATACATTCGAGTGTTCAGTGTTCGAGATGCTTCTGTATGCTCATATTTGTC 1800
Db GTTTAATACATTCGAGTGTTCAGTGTTCGAGATGCTTCTGTATGCTCATATTTGTC 1800
1801 CTAATTTGCCAGTGGGAATCTTAATCAAAATTTGGCTTCTTAATCAAAAGCTTTTAAACCT 1860
Db CTAATTTGCCAGTGGGAATCTTAATCAAAATTTGGCTTCTTAATCAAAAGCTTTTAAACCT 1860
1861 ATTGGTAAGAATGGAGGTGGAGAGCTCCCTGAAGTAAGCAAGAACTTTCTCTTAGT 1920
Db ATTGGTAAGAATGGAGGTGGAGAGCTCCCTGAAGTAAGCAAGAACTTTCTCTTAGT 1920
1921 CGAGCCAAAGTAAAGATGTTCTTAATGTTGCCAGTGTTCGATCTGATGCAAGCAAG 1980
Db CGAGCCAAAGTAAAGATGTTCTTAATGTTGCCAGTGTTCGATCTGATGCAAGCAAG 1980
1981 AAACACTGGGCTTCTAGAACCCAGCACTTGGGAACCTAGACTCCCAAGCTGGACTATGGC 2040
Db AAACACTGGGCTTCTAGAACCCAGCACTTGGGAACCTAGACTCCCAAGCTGGACTATGGC 2040
2041 TCTACTTTCAGCCACATGGCTTAAGAGGTTTCAGAAAGAGTGGGGACAGAGCAAGAC 2100
Db TCTACTTTCAGCCACATGGCTTAAGAGGTTTCAGAAAGAGTGGGGACAGAGCAAGAC 2100
2101 TTTACCTTCATATATTTGTATGATCCCTTAATCAATGATCAATAAATGTTGATGTTGA 2160
Db TTTACCTTCATATATTTGTATGATCCCTTAATCAATGATCAATAAATGTTGATGTTGA 2160
2161 TGAATGTAAATACATGTTTAAACAACTATGATTTTGGAAATTAATCAATGCTATAACTA 2220
Db TGAATGTAAATACATGTTTAAACAACTATGATTTTGGAAATTAATCAATGCTATAACTA 2220
2221 TCTGTATAAAG 2232
Db TCTGTATAAAG 2232

RESULT 2
AAF21105
ID AAF21105 standard; DNA; 143068 BP.
AC AAF21105;
XX
XX
XX 14-MAR-2001 (first entry)
DE Human low adenosine antisense oligonucleotide related sequence #2672.
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; emphysema; pain; cystic fibrosis; allergic rhinitis;
KW chronic obstructive pulmonary disease; pulmonary transplantation rejection;
KW cancer; ss.
XX
XX Homo sapiens.
OS
XX
XX W0200062736-A2.
PN
XX
XX 26-OCT-2000.
PD
XX
XX 24-MAR-2000; 2000WO-US08020.
PF
XX
XX 06-APR-1999; 99US-0127958.
PR
XX
XX (UYEC-) UNIV EAST CAROLINA.
PA

(NYCE/) NYCE J W.
Nyce JW;
WPI; 2000-679539/66.
Low adenosine (A) content antisense oligonucleotides which do not trigger adenosine receptors during metabolism, useful e.g. for treating cancers and respiratory obstructions -
Disclosure; Page 924-957; 1592pp; English.
XX The present invention describes low adenosine (A) content antisense oligonucleotides and compositions (I) comprising them. In the antisense oligonucleotides the A is replaced by a 'Universal' or alternative base. (I) can have respiratory, bronchodilator, antiinflammatory, analgesic, immunosuppressive, antiasthmatic, hypotensive and cytostatic activities. The antisense oligonucleotides and (I) can be used to down-regulate the expression and or activity of target polypeptides associated with lung/respiratory disorders and malignancies, such as stimulating and activating peptide factors and transmitters, transcription factors, immunoglobulins and antibodies, antibody receptors, cytokines and chemokines, endogenously produced specific and non-specific enzymes, binding proteins, adenosine receptors, bradykinin receptors, central chemokine receptors, adenosine receptors, and non-nervous system receptors, CNS and peripheral nervous and non-nervous system peptide transmitters, defensins, growth factors, vasoactive peptides and receptors, binding proteins and malignancy associated proteins. The antisense oligonucleotides may be used in this way to treat disorders including respiratory obstruction (especially pulmonary obstruction and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or surfactant hypoproduction which are associated with a disease or condition selected from pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), pulmonary transplantation rejection, pulmonary infections, bronchitis, and/or cancer. AAF18434 to AAF21543 represent human polynucleotide fragments and antisense oligonucleotides used in the exemplification of the present invention.
XX Sequence 143068 BP; 41194 A; 30122 C; 32403 G; 39349 T; 0 other;
SQ
Query Match 51.6%; Score 1152; DB 21; Length 143068;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 1252; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 979 AGCCTTTTTCACATAGCTCTTGGCTGTAGGATTCCTCCACATCCAAACACCATGTTGTTGGA 1038
Db 48253 AGCCTTTTTCACATAGCTCTTGGCTGTAGGATTCCTCCACATCCAAACACCATGTTGTTGGA 48312
QY 1039 GGTCCAGGAGTGAGACAGGAAAGAAATGTGAAGTGACTACAGAGGCTCTCGATGCT 1098
Db 48313 GGTCCAGGAGTGAGACAGGAAAGAAATGTGAAGTGACTACAGAGGCTCTCGATGCT 48372
QY 1099 CGTGGAAAGAAAGTCAATTTGGCAGAGCCCTGTAAGCCAGTCTTCAGGACAAAGGA 1158
Db 48373 CGTGGAAAGAAAGTCAATTTGGCAGAGCCCTGTAAGCCAGTCTTCAGGACAAAGGA 48432
QY 1159 GCCTAGACAGAGAATGACAGATCTCTCTTTTGGAAATACACAGTCTGGTTCACAGATG 1218
Db 48433 GCCTAGACAGAGAATGACAGATCTCTCTTTTGGAAATACACAGTCTGGTTCACAGATG 48492
QY 1219 TGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACAGGAGGAGGCTGAGAGGAGAG 1278
Db 48493 TGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACAGGAGGAGGCTGAGAGGAGAG 48552
QY 1279 AGACTCCAGCTGGGTTGGAAACAGTATTTTCCAACTACCTTCCAGTTCTCATTTTGG 1338
Db 48553 AGACTCCAGCTGGGTTGGAAACAGTATTTTCCAACTACCTTCCAGTTCTCATTTTGG 48612
QY 1339 AATACAGGATAGAGTTTTCAGACTTTTTTAAATAGTAAATAATTAAGCTGAAAC 1398

2179 TTTAACACACTATGATTGGAAAATAAATCAATGCTATACTATGTGATAAAAG 2232

49453 TTTTACACACTATGATTGGAAAATAAATCAATGCTATACTATGTGATAAAAG 49506

AAA34983
ID AAA34983 standard: DNA; 143068 BP.

28-JUL-2000 (first entry)

XX	Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW	phosphorothioate; impaired respiration; inflammation; allergy;
KW	allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW	antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW	lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW	respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW	pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW	lung cancer; lymphoma; carcinoma; metastasis; ss.

XX
XX
XX

PD 24-FEB-2000:
XX
23-MAR-2000:

PR 03-AUG-1958,
XX
XX

PI NYCE DW,
XX
3000-30

XX New antisease oligonucleotides useful for treating e.g. pulmonary
XX cancer
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancer

xx
ps
Disclosure: Page 851-882; 1343pp; English.

The present invention describes a new composition comprising an antisense oligonucleotide (ON) with low adenosine (up to 15%), which targets nucleic acids involved in bronchoconstriction, allergies, and/or inflammation. The ON can have antiinflammatory, antiallergic, antiasthmatic, cytostatic and analgesic activities. The compositions are useful for the treatment of diseases associated with inflammation, impaired airways, including lung disease and diseases whose secondary effects afflict the lungs of a subject. They can be used for treating e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma, impaired respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease (COPD), and cancers such as leukaemias, lymphomas, carcinomas, and cancers which may metastasise to the lungs, including breast and prostate cancer. The reduction of the adenosine content of the ONs reduces side effects. The A-containing ONs break down with the release of deoxyadenosine which activates adenosine receptors causing bronchoconstriction and inflammation. AAA32313 to AAA33512 represent the nucleotide sequences given in the sequence listing from the present invention, which correspond to SEQ ID NO:1 to 2815, and then the last 195 sequences are also called SEQ ID NO:1 to 185, and then the sequences differ from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to AAA33992) are specifically claimed. ONs from the present invention, N.B. Sequences given in the disclosure of the present invention do not match up with their corresponding SEQ ID NO: sequences given in the sequence listing.

[illegible]

RESULT 7
AAA35151
XX AAA35151 standard; DNA; 149412 BP.
XX
AC
XX AAA35151;
DT 28-JUL-2000 (first entry)
XX
DE Human adenosine receptor related polynucleotide 2nd SEQ ID NO:25.
XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; antisthmatic; cytotatic; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
XX WO200009525-A2.
PN
XX
PD 24-FEB-2000.
XX
XX 03-AUG-1999; 99WO-US17712.
PF
XX 03-AUG-1998; 98US-0095212.
PR
XX (UYEC-) UNIV EAST CAROLINA.
PA
XX
PI Nyce JW;
XX
XX WPI; 2000-205971/18.
DR
XX
XX New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers -
XX
XX Disclosure; Page 1138-1171; 1343pp; English.
PS
XX The present invention describes a new composition comprising an
CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antisthmatic, cytotatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
CC asthma, impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasise to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of
CC the ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA3512 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
CC 195 sequences are also called SEQ ID NO:1 to 185, but the sequences
CC differ from the previously named sequences. SEQ ID NO:11 to 1680
CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
CC invention. N.B. Sequences given in the disclosure of the present
CC invention do not match up with their corresponding SEQ ID NO: sequences
XX given in the sequence listing.
XX
XX Sequence 149412 BP; 43049 A; 31388 C; 33852 G; 41123 T; 0 other;
SQ

	Matches 1252;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Qy 979	AGCCTTTTTCACATAGCTCTTGGGTAGGATGCCCCACTCCAAAACACAGTGTGGA	1038							
Db 54597	AGCCTTTTTCACATAGCTCTTGGGTAGGATGCCCCACTCCAAAACACAGTGTGGA	54656							
Qy 1039	GGTCCAGAGTGCAGACAGGAAAGATGTGAAGTGACTACACAAGGACTCCTCGATGT	1098							
Db 54657	GGTCCAGAGTGCAGACAGGAAAGATGTGAAGTGACTACACAAGGACTCCTCGATGT	54716							
Qy 1099	CCTGAAAGAGAAAGTCAATTGGCAGAGCCCTGAAGCCAGTCTTCAGACAAAGAGGA	1158							
Db 54717	CCTGAAAGAGAAAGTCAATTGGCAGAGCCCTGAAGCCAGTCTTCAGACAAAGAGGA	54776							
Qy 1159	GCCTAGACACAAATGACAGATCTCTGCTTTGGAATCAGACGCTCTGCTTACAGATG	1218							
Db 54777	GCCTAGACACAAATGACAGATCTCTGCTTTGGAATCAGACGCTCTGCTTACAGATG	54836							
Qy 1219	TCTGATTACAGTGTGAATCTTGGTGTCTACGTTACCGCAGGAAAGGCTGAGAGAG	1278							
Db 54837	TCTGATTACAGTGTGAATCTTGGTGTCTACGTTACCGCAGGAAAGGCTGAGAGAG	54896							
Qy 1279	AGACTCCAGCTGGTTGGAAACAGTATTTCCAAACTACCTCCAGTTCCTCATTTT	1338							
Db 54897	AGACTCCAGCTGGTTGGAAACAGTATTTCCAAACTACCTCCAGTTCCTCATTTT	54956							
Qy 1339	AATACAGCATAGATTCAGACTTTTTTAAATAGTAAATAAATAAATAAAGCTGAAAC	1398							
Db 54957	AATACAGCATAGATTCAGACTTTTTTAAATAGTAAATAAATAAATAAAGCTGAAAC	55016							
Qy 1399	TGCAACTTGTAAATGTGTAAGAGTGTGTTGAGTTGCTATCATGTCACACGTGAAAT	1458							
Db 55017	TGCAACTTGTAAATGTGTAAGAGTGTGTTGAGTTGCTATCATGTCACACGTGAAAT	55076							
Qy 1459	GCTGTATTAGTCACAGAGATAATTCTAGCTTTGAGCTTAAAGATTTTGACAGCTGAT	1518							
Db 55077	GCTGTATTAGTCACAGAGATAATTCTAGCTTTGAGCTTAAAGATTTTGACAGCTGAT	55136							
Qy 1519	GTTTGGGAGACTGCTGAGTCAACCCAAATAGTTGTTGATTTGGCAGAGTGTGAGTGTG	1578							
Db 55137	GTTTGGGAGACTGCTGAGTCAACCCAAATAGTTGTTGATTTGGCAGAGTGTGAGTGTG	55196							
Qy 1579	ATCTGTGGGACATATTAGCTTATGTCATGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA	1638							
Db 55197	ATCTGTGGGACATATTAGCTTATGTCATGAGTCAAGTCAAGTCAAGTCAAGTCAAGTCA	55256							
Qy 1639	CAGTATACGCTCCATCGCTGCTCATCTCAGCTGGATCTCCATTCCTCAGGCTTGGTCCA	1698							
Db 55257	CAGTATACGCTCCATCGCTGCTCATCTCAGCTGGATCTCCATTCCTCAGGCTTGGTCCA	55316							
Qy 1699	AAAGCCCTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG	1758							
Db 55317	AAAGCCCTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG	55376							
Qy 1759	GTTCAGTGTCTCCAGATGCTTGTGCTCATATTTCTCCCTAAATTTGGCAGTGGAA	1818							
Db 55377	GTTCAGTGTCTCCAGATGCTTGTGCTCATATTTCTCCCTAAATTTGGCAGTGGAA	55436							
Qy 1819	CTCCTAAATCAAAATGGCTTCTAATCAAGCTTTTAAACCCCTATTGTTGAAGATGGAG	1878							
Db 55437	CTCCTAAATCAAAATGGCTTCTAATCAAGCTTTTAAACCCCTATTGTTGAAGATGGAG	55496							
Qy 1879	GTGAGAGCTCCCTGAGTAGCAAGACATTTCCCTCTTAGTCGAGCCAAAGTTAAGAATG	1938							
Db 55497	GTGAGAGCTCCCTGAGTAGCAAGACATTTCCCTCTTAGTCGAGCCAAAGTTAAGAATG	55556							
Qy 1939	TCTTATCTGTCAGTGTGTTTCTGATCTGATCAAGCAAGAAACACTGGGCTTCTAGA	1998							
Db 55557	TCTTATCTGTCAGTGTGTTTCTGATCTGATCAAGCAAGAAACACTGGGCTTCTAGA	55616							
Qy 1999	ACCAGGCAACTGGGAACCTAGACTCCCAAGCTGGACTATGGCTCTACTTTCAGGCCACAT	2058							
Db 55617	ACCAGGCAACTGGGAACCTAGACTCCCAAGCTGGACTATGGCTCTACTTTCAGGCCACAT	55676							

Query Match
Best Local Similarity

51.6%; Score 1152; DB 21; Length 149412;
99.8%; Pred. No. 0;

QY 2059 GCCTAAGAGGTTTCAGAAAGAGTGGGACAGAGCAGAACTTTCACCTTCATATATTT 2118
 Db 55677 GCCTAAGAGGTTTCAGAAAGAGTGGGACAGAGCAGAACTTTCACCTTCATATATTT 55736
 QY 2119 GTATGATCCCTAATGAATGCATATAATGTTAAGTTGATGGTGAATGTAATACTGTT 2178
 Db 55737 GTATGATCCCTAATGAATGCATATAATGTTAAGTTGATGGTGAATGTAATACTGTT 55796
 QY 2179 TTTAACAACATGATGTTGGAAATATAATCAATGCTATATACTATGTTGATAAAG 2232
 Db 55797 TTTAACAACATGATGTTGGAAATATAATCAATGCTATATACTATGTTGATAAAG 55850

RESULT 8

AAF21273
 ID AAF21273 standard; DNA; 152740 BP.

AC AAF21273;

XX
 DT 14-MAR-2001 (first entry)

XX
 DE Human low adenosine antisense oligonucleotide related sequence #2840.

XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.

XX Homo sapiens.

OS
 PN WO200062736-A2.

XX 26-OCT-2000.

XX 24-MAR-2000; 2000WO-US08020.

XX 06-APR-1999; 99US-0127958.

XX (UYEC-) UNIV EAST CAROLINA.

PA (NYCE/) NYCE J W.

XX Nyce JW;

XX WPI; 2000-679539/66.

XX Low adenosine (A) content antisense oligonucleotides which do not
 trigger adenosine receptors during metabolism, useful e.g. for treating
 cancers and respiratory obstructions -

PS Disclosure; Page 1219-1254; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense
 oligonucleotides and compositions (I) comprising them. In the antisense
 oligonucleotides the A is replaced by a 'Universal' or alternative base.
 (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 The antisense oligonucleotides and (I) can be used to down-regulate the
 expression and/or activity of target polypeptides associated with the
 lung/respiratory disorders and malignancies, such as stimulating and
 activating peptide factors and transmitters, transcription factors,
 immunoglobulins and antibodies, antibody receptors, cytokines and
 chemokines, endogenously produced specific and non-specific enzymes,
 binding proteins, adhesion molecules and their receptors, cytokine and
 chemokine receptors, adenosine receptors, bradykinin receptors, central
 nervous system (CNS) and peripheral nervous and non-nervous system
 receptors, CNS and peripheral nervous and non-nervous system peptide

CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
 CC and/or surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention.

XX

Sequence 152740 BP; 44169 A; 32023 C; 34549 G; 41999 T; 0 other;

Query Match 51.6%; Score 1152; DB 21; Length 152740;
 Best Local Similarity 99.8%; Pred. No. 0;
 Matches 1252; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 979 AGCCTTTTTCACATAGCTCTTGGCTCTAGGATTGCCCTCCCACTCCAAAACACAGTGTGGA 1038
 Db 54597 AGCCTTTTTCACATAGCTCTTGGCTCTAGGATTGCCCTCCAAAACACAGTGTGGA 54656
 QY 1039 GGTCCAGGAGTGAGACCCAGGAAGATGTAAAGTGACTACACAAGGACTCCTCGATGGT 1098
 Db 54657 GGTCCAGGAGTGAGACCCAGGAAGATGTAAAGTGACTACACAAGGACTCCTCGATGGT 54716
 QY 1099 CGTGAAGGAAAGTCAATTCGCGAGAGCCCTGAAGCCAGTCTTCAGGACAAGAGGA 1158
 Db 54717 CGTGAAGGAAAGTCAATTCGCGAGAGCCCTGAAGCCAGTCTTCAGGACAAGAGGA 54776
 QY 1159 GCCTAGACAGAAATGACAGATCTCTGCTTTGGAATCACACGCTTGGCTTCCACAGATG 1218
 Db 54777 GCCTAGACAGAAATGACAGATCTCTGCTTTGGAATCACACGCTTGGCTTCCACAGATG 54836
 QY 1219 TGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACCAGGAGGAGGCTGAGAGAGAG 1278
 Db 54837 TGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACCAGGAGGAGGCTGAGAGAGAG 54896
 QY 1279 AGACTCCAGCTGGGTGGAAACAGTATTTTCCAAACTACCTTCCAGTTCCTCATTTTGG 1338
 Db 54897 AGACTCCAGCTGGGTGGAAACAGTATTTTCCAAACTACCTTCCAGTTCCTCATTTTGG 54956
 QY 1339 AATACAGGCATAGAGTTCAGACTTTTAAATAGTAAATAAATAAAGCTGAAAC 1398
 Db 54957 AATACAGGCATAGAGTTCAGACTTTTAAATAGTAAATAAATAAAGCTGAAAC 55016
 QY 1399 TGCAACTTGTAAATGTGTAAAGAGTGTAGTTGAGTTCTCATGTCAAAAGCTGAATAT 1458
 Db 55017 TGCAACTTGTAAATGTGTAAAGAGTGTAGTTGAGTTCTCATGTCAAAAGCTGAATAT 55076
 QY 1459 GCTGTATTAGTCAGAGATAAATTTCTAGCTTTGAGCTTAAAGAAATTTTTCAGCAGGTTGGTAT 1518
 Db 55077 GCTGTATTAGTCAGAGATAAATTTCTAGCTTTGAGCTTAAAGAAATTTTTCAGCAGGTTGGTAT 55136
 QY 1519 GTTTGGGAGACTGCTGAGTCAACCAATAGTTGTGTTGATGGCAGAGTTGGAAGTGTGTG 1578
 Db 55137 GTTTGGGAGACTGCTGAGTCAACCAATAGTTGTGTTGATGGCAGAGTTGGAAGTGTGTG 55196
 QY 1579 ATCTGGGGCACAATTAGCCCTATGTCATGCGAGCATCTAAAGTAATGATGTCCTTTGAATCA 1638
 Db 55197 ATCTGGGGCACAATTAGCCCTATGTCATGCGAGCATCTAAAGTAATGATGTCCTTTGAATCA 55256
 QY 1639 CAGTATACCTCCATCGCTCATCTCAGCTGGATCTCCATTCTCTCAGGCTTGTGCGCA 1698
 Db 55257 CAGTATACCTCCATCGCTCATCTCAGCTGGATCTCCATTCTCTCAGGCTTGTGCGCA 55316
 QY 1699 AAAGCCTTTTGTGTTTTTGTGTTTTGTATCATATTATGAAGTCATCGCTTAAATACATTCAGT 1758
 Db 55317 AAAGCCTTTTGTGTTTTTGTGTTTTGTATCATATTATGAAGTCATCGCTTAAATACATTCAGT 55376

Mon Jun 2 09:42:04 2003

1759 GTTTCAGTGTTCGAGAGTCTCTGATGCTCATATGTTCCCTAATTTCCAGTGGAA 1818
 55377 GTTTCAGTGTTCGAGAGTCTCTGATGCTCATATGTTCCCTAATTTCCAGTGGAA 55436
 1819 CTCTTAATCAAAATGGCTTCTAATCAAAAGCTTTTAAACCTATTTGTTAAAGATGAAG 1878
 55437 CTCTTAATCAAAATGGCTTCTAATCAAAAGCTTTTAAACCTATTTGTTAAAGATGAAG 55496
 1879 GTGAGAGAGTCCCTGAAGTAAGCAAGAGCTTTCTCTTAGTCGAGCCAGATGAAGT 1938
 55497 GTGAGAGAGTCCCTGAAGTAAGCAAGAGCTTTCTCTTAGTCGAGCCAGATGAAGT 55556
 1939 TTCTTAGTGTCCAGAGTGTCTCTGATGCTGATGCAAGCAAGCAACATGCGGCTTCTAGA 1998
 55557 TTCTTAGTGTCCAGAGTGTCTCTGATGCTGATGCAAGCAAGCAACATGCGGCTTCTAGA 55616
 1999 ACCAGGCAACTTGGGAAGTACAGTCCCAAGCTGAGTACTGCTTACCTTTTACAGCCACAT 2058
 55617 ACCAGGCAACTTGGGAAGTACAGTCCCAAGCTGAGTACTGCTTACCTTTTACAGCCACAT 55676
 2059 GGCTAAAGAGGTTTCAGAAAGAGTGGGGACAGAGCAAGCAACTTTTACCTTCTATATTT 2118
 55677 GGCTAAAGAGGTTTCAGAAAGAGTGGGGACAGAGCAAGCAACTTTTACCTTCTATATTT 55736
 2119 GTATGATCCTTAATGAATGATCAAAATGTTAAGTTGATGTTGAATGAATGAATGAATGAT 2178
 55737 GTATGATCCTTAATGAATGATCAAAATGTTAAGTTGATGTTGAATGAATGAATGAATGAT 55796
 2179 TTTTAACTATGATTTGAAATTAATCAATGCTATATGCTATATGTTGATAAAG 2232
 55797 TTTTAACTATGATTTGAAATTAATCAATGCTATATGCTATATGTTGATAAAG 55850

RESULT 9
 AAQ96298 standard; cDNA; 1979 BP.
 XX
 AC AAQ96298;
 XX
 DT 29-DEC-1995 (first entry)
 XX
 DE Human monocyte chemoattractant protein-1 receptor MCP-1RB.
 XX
 KW Monocyte chemoattractant protein-1 receptor; MCR-1R; chemokine; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 81..1160
 FT /*tag= a
 XX
 PN W09519436-A.
 XX
 PD 20-JUL-1995.
 XX
 PF 11-JAN-1995; 95WO-US00476.
 XX
 PR 13-JAN-1994; 94US-0182962.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Charo I, Coughlin S;
 DR WPI; 1995-263866/34.
 DR P-PSDB; AAR79166.
 XX
 PT DNA encoding monocyte chemo-attractant protein-1 receptor - used partic.
 PT for identifying antagonists and for treating diseases characterised by
 PT monocytic infiltrates
 XX
 PS Disclosure; Fig 2; 84pp; English.
 XX
 CC To identify and clone new members of the chemokine receptor gene

family, degenerate oligo primers were designed corresp. to the conserved sequences R79167 in the second and R79168 in the third transmembrane domains of the MIP-lalpa/RANTES receptor, the IL-8 receptors and the HUMSTRS orphan receptor (Genbank Accession #M99293). The degenerate oligo incorporating EcoRI and XhoI sites at their 5' ends are Q96299 and Q96300. Amplification of cDNA derived from MM6 cells with the primers yielded a number of PCR products. One cDNA appeared to encode a novel protein. To obtain a full-length version of this clone, a MM6 cDNA library was constructed in pFROG and probed with the PCR product. A 2.1 kb cDNA library revealed a second additional clones in the MM6 cDNA library revealed a second sequence that was identical to the 2.1 kb cDNA sequence first obtd. from the 5' UTR through the putative seventh transmembrane domain but contained a different cytoplasmic tail. The second sequence appears to represent alternative splicing of the carboxyl-terminal tail of the MCP-1R protein. The two sequences are denoted MCP-1RA and MCP-1RB (see Q96297/R79165 & Q96298/R79166). Active mature MCP-1RA has a predicted mol. wt. of about 42,000 daltons. MCP-1RB has a mol. wt. of about 41,000 daltons.

Sequence 1979 BP; 530 A; 434 C; 452 G; 563 T; 0 other;
 Query Match 43.9%; Score 980; DB 16; Length 1979;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 980; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GGATTGAACAAGACGACATTTCCCAAGTACATCCCAACATGCTGTCCACATCTCGTTCT 60
 DB 42 GGATTGAACAAGACGACATTTCCCAAGTACATCCCAACATGCTGTCCACATCTCGTTCT 101
 QY 61 CGGTTTATCAGAAATACCAACGAGAGGGTGAAGAGTACCAACCTTTTGTGATTATGAT 120
 DB 102 CGGTTTATCAGAAATACCAACGAGAGGGTGAAGAGTACCAACCTTTTGTGATTATGAT 161
 QY 121 TAGCGTCTCCCTGTCATAAATTTGACGTGAAGCAAAATGGGGCCCAACTCTCGCTCCG 180
 DB 162 TAGCGTCTCCCTGTCATAAATTTGACGTGAAGCAAAATGGGGCCCAACTCTCGCTCCG 221
 QY 181 CTCTACTCGTGTGTTCATCTTTGTTGGGCAACATGCTGGTCTGCTCATCTTA 240
 DB 222 CTCTACTCGTGTGTTCATCTTTGTTGGGCAACATGCTGGTCTGCTCATCTTA 281
 QY 241 ATAACTGCAAAAGCTGAAGTCTTACCTGACATGATTTACCTGCTCAACCTGCCATCTCT 300
 DB 282 ATAACTGCAAAAGCTGAAGTCTTACCTGACATGATTTACCTGCTCAACCTGCCATCTCT 341
 QY 301 GATCTGCTTTTCTTATTACTCTCCCATTTGTTGGGCTACTCTGCTGCAAAATGAGTGGTC 360
 DB 342 GATCTGCTTTTCTTATTACTCTCCCATTTGTTGGGCTACTCTGCTGCAAAATGAGTGGTC 401
 QY 361 TTTGGGAATGCAATGTGCAAAATTTACAGGGCTGATACATGGTATTATTGGCGGA 420
 DB 402 TTTGGGAATGCAATGTGCAAAATTTACAGGGCTGATACATGGTATTATTGGCGGA 461
 QY 421 ATCTTCTCATCATCTCTGACATGATAGATACCTGGCTATTGTCATGCTGTGTTT 480
 DB 462 ATCTTCTCATCATCTCTGACATGATAGATACCTGGCTATTGTCATGCTGTGTTT 521
 QY 481 GCTTTAAAGCCAGGACGGTCACTTTGGGGTGGTGACAAGTGTATCATCCTGGTGGTG 540
 DB 522 GCTTTAAAGCCAGGACGGTCACTTTGGGGTGGTGACAAGTGTATCATCCTGGTGGTG 581
 QY 541 GCTGTGTTTGTCTTCTCCAGGAATCATCTTTTACTAAATGCCAGAAAGATTTCTGTT 600
 DB 582 GCTGTGTTTGTCTTCTCCAGGAATCATCTTTTACTAAATGCCAGAAAGATTTCTGTT 641
 QY 601 TATGCTGTGGCCCTTATTTTCCAGGAGATGGAATTAATTTCCACACAATATGAGGAAC 660
 DB 642 TATGCTGTGGCCCTTATTTTCCAGGAGATGGAATTAATTTCCACACAATATGAGGAAC 701
 QY 661 ATTTTGGGCTGGTCTGCGGTGCTCATGCTGCTACTGCTGCGGAATCCCGAA 720
 DB 702 ATTTTGGGCTGGTCTGCGGTGCTCATGCTGCTACTGCTGCGGAATCCCGAA 761

D	AAAS12139	standard; DNA; 1083 BP.
XX	AAAS12139;	
CC	04-DEC-2001	(first entry)
XX	Human CCR2-64I	polymorphic variant polynucleotide.
XX	Human; CCR2 receptor; CCR2-64I; CCR2-64V; gene therapy; atherosclerosis;	
XX	single nucleotide polymorphism; hypercholesterolaemia; ds.	
XX	Homo sapiens.	
XX	Key	Location/Qualifiers
XX	variation	replace(190,G)
XX	FT	/*tag= a
XX	FT	/standard_name= "Single nucleotide polymorphism"
XX	W0200162796-A1.	
XX	30-AUG-2001.	
XX	22-FEB-2001; 2001WO-GB00755.	
XX	22-FEB-2000; 2000GB-0004183.	
XX	(SMK) SMITHKLINE BEECHAM PLC.	
XX	Valdes AM, Groot PHE, Spurr NK;	
XX	WPI; 2001-550086/61.	
XX	P-PSDB; AAU07613.	
XX	Diagnosing atherosclerosis or susceptibility to atherosclerosis in a	
XX	subject, by determining a single nucleotide polymorphism in specific	
XX	codon of a polynucleotide encoding human CCR2 receptor in genome of the	
XX	subject -	
XX	Claim 3; Page 20; 28pp; English.	
XX	The invention relates to diagnosing atherosclerosis (or susceptibility	
XX	to) in a subject by determining expression or activity of the human	
XX	CCR2-64I polypeptide (a polymorphic variant form of the human CCR2	
XX	receptor) or the CCR2-64V polypeptide (human CCR2 receptor), by screening	
XX	for a single nucleotide polymorphism in codon 64 of the polynucleotide	
XX	encoding the CCR2 receptor. This results in production of CCR2-64I,	
XX	whereby polymorphic variants are associated with a lower incidence of	
XX	atherosclerosis. The presence or amount of CCR2-64I/V in a sample can	
XX	also be analysed. The sequences of the invention can be used for	
XX	predicting the response of a patient to drug treatment, for predicting	
XX	the disease outcome in a patient and also for the production of a	
XX	treatment for hypercholesterolaemia. The sequence represents DNA encoding	
XX	the polymorphic variant polypeptide CCR2-64I.	
XX	Sequence 1083 BP; 256 A; 260 C; 246 G; 321 T; 0 other;	
XX	Query Match	39.9%; Score 890; DB 22; Length 1083;
XX	Best Local Similarity	99.9%; Pred No. 0;
XX	Matches	940; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy	40	ATGCTGTCCACATCTCGTTCTTCGGTTTATCAGAATACCAACGAGAGCGGTGAAGAAGTC 99
Db	1	ATGCTGTCCACATCTCGTTCTTCGGTTTATCAGAATACCAACGAGAGCGGTGAAGAAGTC 60
Qy	100	ACCACCTTTTGTGATTATGATACGGTGCTCCCTGTCTATAATTTGACGTGAAGCAAAAT 159
Db	61	ACCACCTTTTGTGATTATGATACGGTGCTCCCTGTCTATAATTTGACGTGAAGCAAAAT 120
Qy	160	GGGGGCCCAACTCCTGCCCTCCGCTCTACRCGCTGGTGTTTCATCTTTGGTTTGTGGGCAAC 219
Db	121	GGGGGCCCAACTCCTGCCCTCCGCTCTACRCGCTGGTGTTTCATCTTTGGTTTGTGGGCAAC 180
Qy	220	ATGCTGGTGGCTCCTCATCTTAATAAATCGCAAAAGCTGAACTGCTTCACTGACATTTTAC 279

XX 16-SEP-1997.
PD
XX
XX 11-MAR-1996; 96JP-0053574.
XX
XX 11-MAR-1996; 96JP-0053574.
XX
XX (TAKE) TAKEDA CHEM IND LTD.
XX
XX WPI; 1997-506557/47.
DR P-PSDB; AAW35833.
XX
XX DNA encoding human monocyte chemoattractant protein 1 receptor -
PT used to treat tumours and inflammatory, viral, infectious, allergic,
PT diabetic and central nervous system diseases
XX
XX Claim 1; Page 12; 15pp; Japanese.
XX
XX The present sequence encodes human monocyte chemoattractant protein 1
CC (MCP-1) receptor protein. The MCP-1 receptor protein and encoding DNA
CC are used for the prevention and treatment of tumours and inflammatory,
CC viral, infectious, allergic, diabetic and central nervous system
CC diseases.
XX
XX Sequence 1083 BP; 257 A; 259 C; 245 G; 322 T; 0 Other;
SQ
Query Match 37.6%; Score 839; DB 18; Length 1083;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 939; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 40 ATGCTGTCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAATC 99
Db 1 ATGCTGTCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAATC 60
QY 100 ACCACCTTTTTCATTATCATACGGTGCCTCCTGTCATAAATTTGACGTGAAGCAAAAT 159
Db 61 ACCACCTTTTTCATTATCATACGGTGCCTCCTGTCATAAATTTGACGTGAAGCAAAAT 120
QY 160 GGGGCCCAACTCGCTCCGCTACTCGCTGGTGTTCATCTTTGGTTTGTGGGCAAC 219
Db 121 GGGGCCCAACTCGCTCCGCTACTCGCTGGTGTTCATCTTTGGTTTGTGGGCAAC 180
QY 220 ATGCTGGTGGCTCCTCATCTTATAAAGTCAAAAGCTGAAGTGTGACGTGACATTTAC 279
Db 181 ATGCTGGTGGCTCCTCATCTTATAAAGTCAAAAGCTGAAGTGTGACGTGACATTTAC 240
QY 280 CTGCTCAACCTGGCCATCTCTGATCTGCTTTTCTTATTACTCTCCCATTTGGGCTCAC 339
Db 241 CTGCTCAACCTGGCCATCTCTGATCTGCTTTTCTTATTACTCTCCCATTTGGGCTCAC 300
QY 340 TCTGCTGCAATAGTGGGTCTTTGGGATGCAATGTGCAAAATTTACAGGCGCTGTAT 399
Db 301 TCTGCTGCAATAGTGGGTCTTTGGGATGCAATGTGCAAAATTTACAGGCGCTGTAT 360
QY 400 CACATCGGTTATTTGGCGGAATCTTCTCATCATCTCCTCGACAATCGATACCTG 459
Db 361 CACATCGGTTATTTGGCGGAATCTTCTCATCATCTCCTCGACAATCGATACCTG 420
QY 460 GCTATTGTCCATGCTGTTGCTTTAAAGCCAGGACGTCACCTTTGGGGTGGTGACA 519
Db 421 GCTATTGTCCATGCTGTTGCTTTAAAGCCAGGACGTCACCTTTGGGGTGGTGACA 480
QY 520 AGTGTATCACTGGTTGGTGGTGTGTTTGTCTGTCTCCAGGAATCATCTTTACTAAA 579
Db 481 AGTGTATCACTGGTTGGTGGTGTGTTTGTCTGTCTCCAGGAATCATCTTTACTAAA 540
QY 580 TGCCAGAAAGAAATCTGTTTATGCTGTGGCCCTTATTTCCAGGAGATGGAATAAT 639
Db 541 TGCCAGAAAGAAATCTGTTTATGCTGTGGCCCTTATTTCCAGGAGATGGAATAAT 600
QY 640 TTCCACAATAATAGGAACATTTTGGGGCTGGTCTCCCGCTGCTCATCATGTCATC 699
Db 601 TTCCACAATAATAGGAACATTTTGGGGCTGGTCTCCCGCTGCTCATCATGTCATC 660

QY	40	ATGCTGCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAATC	99
DB	1	ATGCTGCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGCGGTGAAGAATC	60
QY	100	ACCACCTTTTGTGATTATGATTACGGTCTCCCTGCTATAAATTTGACGTGAAGCAAT	159
DB	61	ACCACCTTTTGTGATTATGATTACGGTCTCCCTGCTATAAATTTGACGTGAAGCAAT	120
QY	160	GGGGCCCAACTCCCTCCGCTCTACTCGCTGGTGTTCATCTTTGGTTTCTTGGGCAAC	219
DB	121	GGGGCCCAACTCCCTCCGCTCTACTCGCTGGTGTTCATCTTTGGTTTCTTGGGCAAC	180
QY	220	ATGCTGGTGGTCCCTCATCTTATAAATGCAAAAAGCTGAAGTGTGTGACTGACATTTAC	279
DB	181	ATGCTGGTGGTCCCTCATCTTATAAATGCAAAAAGCTGAAGTGTGTGACTGACATTTAC	240
QY	280	CTGCTCAACCTGGCAATCTCATCTGCTTTTCTTATTTACTCTCCCATTTGGGCTCAC	339
DB	241	CTGCTCAACCTGGCAATCTCATCTGCTTTTCTTATTTACTCTCCCATTTGGGCTCAC	300
QY	340	CTGCTGCAAAATGAGTGGTCTTTTGGGAATGCAATGTCAAAATATTTCACAGGGCTGAT	399
DB	301	CTGCTGCAAAATGAGTGGTCTTTTGGGAATGCAATGTCAAAATATTTCACAGGGCTGAT	360
QY	400	CACATCGGTATTTTGGGGAATCTTCTTCATCATCTCTCTGCAATCGATAGATACCTG	459
DB	361	CACATCGGTATTTTGGGGAATCTTCTTCATCATCTCTCTGCAATCGATAGATACCTG	420
QY	460	GCTATTGTCCATCTGTGTTTGCTTTAAAAGCCAGACGGTCACTTTGGGTTGGTGACA	519
DB	421	GCTATTGTCCATCTGTGTTTGCTTTAAAAGCCAGACGGTCACTTTGGGTTGGTGACA	480
QY	520	AGTGTGATCACTGGTTGGTGGCTGTGTTTGGCTCTCTGCCAGGAATCATCTTTACTAAA	579
DB	481	AGTGTGATCACTGGTTGGTGGCTGTGTTTGGCTCTCTGCCAGGAATCATCTTTACTAAA	540
QY	580	TGCCAGAAAAGAAATTCGTTTATGTCTGTGGCCCTTATTTCACGAGGATGGAATAAT	639
DB	541	TGCCAGAAAAGAAATTCGTTTATGTCTGTGGCCCTTATTTCACGAGGATGGAATAAT	600
QY	640	TTCCACACATAATATGAGAACATTTTGGGCTGGTCTGCCGCTGCTCATCATGCTCATC	699
DB	601	TTCCACACATAATATGAGAACATTTTGGGCTGGTCTGCCGCTGCTCATCATGCTCATC	660
QY	700	TGCTACTCGGGAATCCTGAAAACCTGCTTCGGTGTGAAAACGAGAGAAGAGGCATAGG	759
DB	661	TGCTACTCGGGAATCCTGAAAACCTGCTTCGGTGTGAAAACGAGAGAAGAGGCATAGG	720
QY	760	GCACTGAGAGTCACTTCCACATCATGATTTGTTTACTTCTCTCTGCACTCCCTATTAAC	819
DB	721	GCAAGAGAGTCACTTCCACATCATGATTTGTTTACTTCTCTCTGCACTCCCTATTAAC	780
QY	820	ATTGTGATCTCTCCGCAACCTTCCAGGAATCTTTCGGCTGAGTAACCTGTGAAAAGCAC	879
DB	781	ATTGTGATCTCTCCGCAACCTTCCAGGAATCTTTCGGCTGAGTAACCTGTGAAAAGCAC	840
QY	880	AGTCAACTGGCAAGCCACGAGGTGACAGAGACTCTTGGGATGACTCCTGCTGCTC	939
DB	841	AGTCAACTGGCAAGCCACGAGGTGACAGAGACTCTTGGGATGACTCCTGCTGCTC	900
QY	940	AATCCCATCATCTATGCTCTCTGTTGGGGAAGAGTTTCAGAAAG	980
DB	901	AATCCCATCATCTATGCTCTCTGTTGGGGAAGAGTTTCAGAAAG	941
RESULT 14			
AAV84136			
ID	AAV84136 standard; DNA; 461 BP.		
XX			
AC	AAV84136;		
XX			
DT	15-MAR-1999 (first entry)		

